Clinical Trial Update: Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety and tolerability of converting relapsing multiple sclerosis patients from oral, injectable, or infusion disease-modifying therapi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing Multiple Sclerosis

Drugs mentioned

• MAYZENT (siponimod)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Multiple Sclerosis, Relapsing Multiple Sclerosis | Phase 3 | Status: COMPLETED | Results posted: 2023-07-20